Last reviewed · How we verify
Auto CAR-T
At a glance
| Generic name | Auto CAR-T |
|---|---|
| Sponsor | Hebei Senlang Biotechnology Inc., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Descartes-08 for Patients With Systemic Lupus Erythematosus (PHASE2)
- Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL (PHASE2)
- Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT (PHASE1, PHASE2)
- Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma (PHASE2)
- A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases (PHASE1)
- RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies (PHASE1)
- Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells (PHASE2)
- CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients? (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Auto CAR-T CI brief — competitive landscape report
- Auto CAR-T updates RSS · CI watch RSS
- Hebei Senlang Biotechnology Inc., Ltd. portfolio CI